At a glance
ClinicalIndex Comparison RecordN/ACompleted· 312 enrolled
Drug / intervention
Blood sampleother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
In Brief
An observational study evaluating Blood sample for Cancer. Completed, enrolled 312 participants across 2 sites.
Detailed Summary
In order to assess the important issue of the safety of antiangiogenic TKI in geriatric population we set up this project which aims to identify, among clinical, biological, pharmacokinetic data, predictive factors for severe toxicity of antiangiogenic TKI (sunitinib, sorafenib, pazopanib, regorafenib, axitinib) in patients over 70 year-old.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesFrance
CollaboratorsAgence Nationale de sécurité du Médicament
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedApr 2016
Primary CompletionNov 2019
TodayJul 2026
First PostedApr 26, 2016
Enrollment StartFeb 2, 2016
Primary CompletionNov 19, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.2 years ago
Interventions
Blood sampleother
One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic